trending Market Intelligence /marketintelligence/en/news-insights/trending/M3vf3qj997oNNOBmXLdafA2 content esgSubNav
In This List

Report: Gilead, GlaxoSmithKline mulling bids for United Therapeutics

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond


Report: Gilead, GlaxoSmithKline mulling bids for United Therapeutics

Gilead Sciences Inc. and GlaxoSmithKline plc are among suitors weighing bids for United Therapeutics Corp., the Evening Standard reported Aug. 4, citing anonymous sources.

The news outlet reported that Gilead is most likely to win a bid, while Novartis AG is another possible contender. According to the anonymous sources, United could be worth as much as $200 per share in a sale, making the purchase price around $8.7 billion.

GSK is being advised by Lazard and Citi in the process, the Evening Standard reported.